Denosumab and MRONJ Risk in Dentistry

Drug group: Denosumab

Common brand examples: Prolia, Xgeva

German terms: Denosumab, Antiresorptivum, RANKL-Inhibitor, Kiefernekrose, medikamentenassoziierte Kiefernekrose, MRONJ

Dental relevance: MRONJ risk assessment before extractions, implants, periodontal surgery, apical surgery, denture trauma management, and dentoalveolar surgery.

Key principle: Denosumab should never be stopped or delayed by the dentist alone. Dental planning must balance jaw healing risk against systemic risks, especially rebound vertebral fractures after delayed or stopped osteoporosis dosing.

This article is for dental education only. Denosumab is used for osteoporosis and also in higher-dose oncology regimens for bone metastases or skeletal-related event prevention. The medical indication and dose strongly change MRONJ risk. Do not advise a denosumab drug holiday, dose delay, or permanent discontinuation without coordination with the prescribing physician, oncologist, endocrinologist, or osteoporosis specialist.

Denosumab is an antiresorptive monoclonal antibody that inhibits RANKL. By reducing osteoclast formation and activity, it decreases bone resorption. This is useful in osteoporosis and cancer-related bone disease, but it also creates a medication-related osteonecrosis of the jaw risk.

Dental risk is not the same for every denosumab patient. A patient receiving Prolia for osteoporosis generally has a lower MRONJ risk than a patient receiving high-dose Xgeva for metastatic cancer, but both require medication history, risk assessment, prevention, and careful planning before invasive dental treatment.

The key clinical principle is: avoid unnecessary dentoalveolar trauma, but do not ignore infection. Untreated periodontitis, periapical infection, denture trauma, and non-restorable teeth can themselves become MRONJ triggers.

• Best dental approach: prevention, early infection control, careful risk stratification, and coordinated invasive-care planning.
• Main dental risk: non-healing jaw bone exposure after extraction, denture trauma, surgery, or infection.
• Highest risk group: oncology patients receiving high-dose denosumab, especially with chemotherapy, steroids, antiangiogenic therapy, diabetes, smoking, or poor oral health.
• Lower risk group: many osteoporosis patients on six-month denosumab dosing, but risk is not zero.
• Clinical priority: know the indication, dose, last injection, next injection date, duration, comorbidities, and planned procedure risk.

Denosumab blocks RANKL, a key signal required for osteoclast development and activation. When RANKL is inhibited, osteoclast activity decreases and bone resorption falls.

• Therapeutic effect: reduced bone resorption and reduced fracture or skeletal-event risk depending on indication.
• Dental concern: reduced bone turnover can impair healing after jaw trauma, extraction, infection, or denture injury.
• Difference from bisphosphonates: denosumab does not bind to bone in the same long-lasting way, but its dosing schedule is medically important.
• Important safety issue: delayed or stopped osteoporosis denosumab can be associated with rebound bone turnover and vertebral fracture risk, so dental timing must be medically coordinated.

Medication-related osteonecrosis of the jaw is usually considered when a patient exposed to antiresorptive or antiangiogenic medication develops exposed bone, or bone that can be probed through an intraoral or extraoral fistula, persisting for more than eight weeks, without prior jaw radiation or jaw metastasis.

• Exposed yellow-white bone that does not heal
• Non-healing extraction socket
• Pain, swelling, pus, fistula, or infection
• Loose teeth or unexplained periodontal breakdown
• Numbness, altered sensation, sinus involvement, or pathologic fracture in advanced cases
• May appear after extraction, implant surgery, periodontal disease, denture trauma, or sometimes without obvious trauma

• Indication: osteoporosis treatment is usually lower risk than cancer-related high-dose therapy.
• Dose and interval: Prolia-style osteoporosis dosing differs from Xgeva-style oncology dosing.
• Duration: longer therapy and cumulative exposure may increase risk.
• Dental procedure: extraction, implant placement, periodontal surgery, apical surgery, and bone surgery carry more risk than routine restorative care.
• Local disease: periodontitis, periapical infection, non-restorable teeth, sharp bone, and denture trauma increase risk.
• Systemic factors: diabetes, corticosteroids, chemotherapy, antiangiogenic drugs, smoking, immunosuppression, anemia, and poor nutrition may increase risk.

• Ask for the exact drug name, brand, dose, indication, duration, last injection date, and next injection date.
• Identify whether denosumab is for osteoporosis or cancer-related bone disease.
• Ask about previous MRONJ, non-healing socket, exposed bone, jaw pain, altered sensation, or fistula.
• Prioritize prevention: caries control, periodontal care, denture adjustment, oral hygiene, and recall.
• Prefer conservative care when it can remove infection predictably without bone trauma.
• Coordinate invasive dental treatment with the prescribing clinician, especially if timing relative to injection is being considered.
• Use atraumatic technique, infection control, local hemostasis, appropriate closure when indicated, and close postoperative review.
• Refer high-risk oncology patients or complex surgical cases to oral surgery or specialist care.

• Current or previous MRONJ without specialist input
• High-dose oncology denosumab with elective invasive procedure planned
• Non-urgent extraction where endodontic, periodontal, restorative, or palliative options are reasonable
• Exposed bone, non-healing socket, unexplained jaw pain, fistula, or suspected MRONJ
• Uncontrolled dental infection or systemic instability requiring coordination first
• Implant planning in a high-risk patient without specialist risk assessment
• Patient does not understand MRONJ risk, alternatives, and follow-up needs

Denosumab timing is different from bisphosphonate timing. Because denosumab does not remain bound in bone like bisphosphonates, timing dental surgery between doses may be discussed in some patients. However, excessive delay or discontinuation can be medically dangerous, especially in osteoporosis patients because of rebound vertebral fracture risk.

• Osteoporosis dosing: if invasive dental care is needed, coordinate timing with the prescriber rather than independently delaying the next injection.
• After extraction: some guidance recommends delaying the next denosumab dose until soft tissue or socket healing is adequate, but this must be medically coordinated.
• Oncology dosing: high-dose denosumab patients usually need specialist coordination before invasive dental procedures.
• Never do this: tell the patient to skip, stop, or delay denosumab without the prescribing clinician.

• Complete dental assessment before starting high-dose denosumab when possible.
• Remove hopeless teeth and treat active infection before therapy if medically feasible.
• Maintain periodontal health and stable oral hygiene during therapy.
• Adjust dentures early to prevent chronic mucosal trauma.
• Use fluoride and caries-prevention strategies to avoid future extractions.
• Review high-risk patients regularly and respond early to pain, mobility, swelling, fistula, or exposed bone.
• Educate patients to tell every dentist about denosumab and to report jaw symptoms immediately.
• Document medication history and MRONJ risk discussion at each invasive-care planning stage.

• Exposed bone or bone visible/probeable through a fistula
• Non-healing extraction socket after several weeks
• Jaw pain, swelling, pus, fistula, or unexplained bad taste
• Loose teeth without clear periodontal explanation
• Numbness, tingling, altered sensation, or “heavy jaw” feeling
• Denture sore that does not heal after adjustment
• Sinus symptoms after upper jaw procedures
• Pathologic fracture suspicion or severe persistent bone pain

With denosumab, the dental question is not simply “extract or do not extract.” The real question is: What is the medical indication, when was the last dose, when is the next dose, can infection be controlled conservatively, and who must coordinate the timing?

• Bisphosphonates and MRONJ Risk
• Antiresorptive Drugs
• Medication-Related Osteonecrosis of the Jaw
• Dental Extraction Risk Assessment
• Denture Trauma and MRONJ
• Implants in Medically Complex Patients
• Osteoporosis Medications
• Oncology Bone-Modifying Agents
• Oral Surgery Referral
• Dental Prevention Before Antiresorptive Therapy

Denosumab is an antiresorptive RANKL inhibitor associated with medication-related osteonecrosis of the jaw. Dental risk depends strongly on the indication, dose, duration, last and next injection dates, local infection, planned procedure, and systemic risk factors. Osteoporosis patients on six-month dosing usually have lower risk than oncology patients receiving high-dose therapy, but invasive dental care still requires careful planning. Unlike bisphosphonates, denosumab does not bind bone for years, yet stopping or delaying it can create serious systemic risks, especially rebound vertebral fractures in osteoporosis patients. Therefore, dentists should not independently stop or delay denosumab. The safest dental strategy is prevention, early infection control, denture trauma management, conservative treatment where possible, medical coordination for invasive procedures, atraumatic technique, and close postoperative review.